[多佐胺/噻吗洛尔固定组合（多佐替莫尔）对原发性开角型青光眼的疗效和安全性]。

Q3 Medicine

Vestnik oftalmologii Pub Date : 2024-01-01 DOI:10.17116/oftalma2024140051125

E V Karlova, E B Eroshevskaya

{"title":"[多佐胺/噻吗洛尔固定组合（多佐替莫尔）对原发性开角型青光眼的疗效和安全性]。","authors":"E V Karlova, E B Eroshevskaya","doi":"10.17116/oftalma2024140051125","DOIUrl":null,"url":null,"abstract":"Safe and effective glaucoma treatment remains a critical task in ophthalmology. Newly introduced medications, in addition to mandatory registration trials, are also evaluated in real-world clinical settings.Purpose: This study assesses the efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in patients with primary open-angle glaucoma (POAG) in real-world clinical settings.Material and methods: The study included 55 patients aged 46 to 75 years with stage I and II POAG. The initial mean intraocular pressure (IOP) was 24.07±1.31 mm Hg. All patients were prescribed the fixed combination of dorzolamide/timolol.Results: The mean IOP after 1, 3, 6, and 12 weeks of therapy was 19.20±2.46, 18.48±2.04, 17.88±1.88, and 17.62±1.63 mm Hg, respectively. After 12 weeks of therapy, IOP reduction to 18 mm Hg was observed in 63.64% of patients, a reduction of 20% or more from baseline in 81.82% of patients, and a reduction of 30% or more in 14.55% of patients. No serious adverse events were recorded during the observation period.Conclusion: This study confirms the high hypotensive efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol).","PeriodicalId":23529,"journal":{"name":"Vestnik oftalmologii","volume":"140 5","pages":"125-129"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma].\",\"authors\":\"E V Karlova, E B Eroshevskaya\",\"doi\":\"10.17116/oftalma2024140051125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Safe and effective glaucoma treatment remains a critical task in ophthalmology. Newly introduced medications, in addition to mandatory registration trials, are also evaluated in real-world clinical settings.Purpose: This study assesses the efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in patients with primary open-angle glaucoma (POAG) in real-world clinical settings.Material and methods: The study included 55 patients aged 46 to 75 years with stage I and II POAG. The initial mean intraocular pressure (IOP) was 24.07±1.31 mm Hg. All patients were prescribed the fixed combination of dorzolamide/timolol.Results: The mean IOP after 1, 3, 6, and 12 weeks of therapy was 19.20±2.46, 18.48±2.04, 17.88±1.88, and 17.62±1.63 mm Hg, respectively. After 12 weeks of therapy, IOP reduction to 18 mm Hg was observed in 63.64% of patients, a reduction of 20% or more from baseline in 81.82% of patients, and a reduction of 30% or more in 14.55% of patients. No serious adverse events were recorded during the observation period.Conclusion: This study confirms the high hypotensive efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol).\",\"PeriodicalId\":23529,\"journal\":{\"name\":\"Vestnik oftalmologii\",\"volume\":\"140 5\",\"pages\":\"125-129\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vestnik oftalmologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17116/oftalma2024140051125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik oftalmologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/oftalma2024140051125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

安全有效地治疗青光眼仍然是眼科领域的一项重要任务。目的：本研究评估了原发性开角型青光眼（POAG）患者在实际临床环境中使用多佐胺/噻吗洛尔（Dorzotimol）固定联合用药的疗效和安全性：研究纳入了 55 名年龄在 46 岁至 75 岁之间的 I 期和 II 期 POAG 患者。初始平均眼压（IOP）为 24.07±1.31 mm Hg。所有患者均处方多佐胺/噻吗洛尔固定组合：治疗 1、3、6 和 12 周后的平均眼压分别为（19.20±2.46）、（18.48±2.04）、（17.88±1.88）和（17.62±1.63）毫米汞柱。治疗 12 周后，63.64% 的患者眼压降至 18 毫米汞柱，81.82% 的患者眼压比基线降低 20% 或更多，14.55% 的患者眼压降低 30% 或更多。观察期间未出现严重不良反应：这项研究证实了多佐胺/噻吗洛尔固定联合用药（多佐替莫尔）具有很高的降压疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma].

Safe and effective glaucoma treatment remains a critical task in ophthalmology. Newly introduced medications, in addition to mandatory registration trials, are also evaluated in real-world clinical settings.

Purpose: This study assesses the efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in patients with primary open-angle glaucoma (POAG) in real-world clinical settings.

Material and methods: The study included 55 patients aged 46 to 75 years with stage I and II POAG. The initial mean intraocular pressure (IOP) was 24.07±1.31 mm Hg. All patients were prescribed the fixed combination of dorzolamide/timolol.

Results: The mean IOP after 1, 3, 6, and 12 weeks of therapy was 19.20±2.46, 18.48±2.04, 17.88±1.88, and 17.62±1.63 mm Hg, respectively. After 12 weeks of therapy, IOP reduction to 18 mm Hg was observed in 63.64% of patients, a reduction of 20% or more from baseline in 81.82% of patients, and a reduction of 30% or more in 14.55% of patients. No serious adverse events were recorded during the observation period.

Conclusion: This study confirms the high hypotensive efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vestnik oftalmologii Medicine-Ophthalmology

CiteScore

0.80

自引率

0.00%

发文量

129

期刊介绍： The journal publishes materials on the diagnosis and treatment of eye diseases, hygiene of vision, prevention of ophthalmic affections, history of Russian ophthalmology, organization of ophthalmological aid to the population, as well as the problems of special equipment. Original scientific articles and surveys on urgent problems of theory and practice of Russian and foreign ophthalmology are published. The journal contains book reviews on ophthalmology, information on the activities of ophthalmologists" scientific societies, chronicle of congresses and conferences.The journal is intended for ophthalmologists and scientific workers dealing with clinical problems of diseases of the eye and physiology of vision.